Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

The Role of Conformational Diseases on Macrophage Function

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

Who May Be Eligible (Plain English)

Who May Qualify: - Signed willing to sign a consent form - Male or female 18 years of age or older - Negative pregnancy test for women of childbearing potential - Hemoglobin \>12.5 g/dl measured on the day of participation - Negative urine nicotine test Who Should NOT Join This Trial: - Pregnancy or breastfeeding - Weight \< 50 kg - History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months - Known hemoglobin \<12.5 g/dl within the past 90 days - Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \>100 mmHg - Poor venous access - Large volume blood donation (\>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking) - Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition) - Psychiatric or cognitive disturbance or illness that would affect subject safety - Current smoker Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Signed informed consent * Male or female 18 years of age or older * Negative pregnancy test for women of childbearing potential * Hemoglobin \>12.5 g/dl measured on the day of participation * Negative urine nicotine test Exclusion Criteria: * Pregnancy or breastfeeding * Weight \< 50 kg * History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months * Known hemoglobin \<12.5 g/dl within the past 90 days * Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \>100 mmHg * Poor venous access * Large volume blood donation (\>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking) * Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition) * Psychiatric or cognitive disturbance or illness that would affect subject safety * Current smoker

Treatments Being Tested

PROCEDURE

History and physical exam.

At every study visit, participant's will be asked about their medical history and will have a physical exam.

PROCEDURE

Blood draw.

At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

PROCEDURE

Pulmonary function testing.

At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

DRUG

Albuterol inhaler.

At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Locations (1)

Shands at the University of Florida
Gainesville, Florida, United States